Market Overview

Gilead Sciences Outlook Brightens; Citi Upgrades

Gilead Sciences Outlook Brightens; Citi Upgrades
Related GILD
Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season
Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather'
Powerhouse Duo Takes On Gilead, Allergan In Liver Disease, But Stocks Dip (Investor's Business Daily)

Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharma company focused on treatments for HIV/AIDS, liver disease, cancer, inflammatory and respiratory, and cardiovascular conditions.

The Analyst

Citigroup analyst Robyn Karnauskas upgraded shares of Gilead Sciences from Neutral to Buy, with a $103 price target.

The Thesis

Hepatitis C Virus stabilization by mid-2018 and tax reform has improved the outlook for Gilead Sciences, Karnauskas said in a note.

Given the management's statement at the JPMorgan Healthcare Conference that HCV is becoming more predictable, the analyst said post-earnings the HCV numbers could become more reasonable.

Citi expects pipeline catalysts, with JAK-1 and NASH, or non-alcoholic steatohepatitis, to start outweighing HCV declines. The firm also sees plenty of pipeline catalysts, including:

  • NASH phase 2 readouts at the European Association for the Study of the Liver;
  • Major Phase 3 readout for STELLER 4 early next year; and
  • First Phase 3 readout for JAK-1 program likely in the second-half of 2018.

"All eyes would also be on Juno Therapeutics safety data and differentiation vs. Kite Pharma CAR-T in mid-2018," Karnauskas said. Gilead purchased Kite Pharma last October.

Price Action

Gilead Sciences shares are up over 22 percent over the past year. At time of writing, shares were down 1.8 percent to $87.20.

Related Links:

Pete Najarian Sees Unusual Options Activity In Gilead And KKR & Co

Pharma M&A Picks Up Momentum

Latest Ratings for GILD

Mar 2018BarclaysMaintainsOverweightOverweight
Feb 2018BMO CapitalMaintainsOutperformMarket Perform
Feb 2018Leerink SwannMaintainsMarket PerformMarket Perform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Citigroup Robyn KarnauskasAnalyst Color Upgrades Analyst Ratings Best of Benzinga


Related Articles (GILD + JUNO)

View Comments and Join the Discussion!